Drug intelligence / Profile preview

IB-001

Development stage: Phase 1
Lead developer: Intrepida Bio
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

IB-001 is a monoclonal antibody designed to function as an inhibitor of BAG3 (BAG cochaperone 3). BAG3 is a protein crucial for maintaining cellular proteostasis and is implicated in the pathogenesis of various conditions, including cancer, neurodegenerative disorders, and cardiac dysfunction. By inhibiting BAG3, IB-001 aims to modulate its activity and potentially interfere with these disease pathways.

Targets

BAG3 (Bcl2-associated athanogene 3)

Beyond the preview

Go deeper on IB-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IB-001.

Explore the full profile